Blood Journals reports that fewer than half of FDA-approved CAR T indications are publicly reimbursed across the G20, highlighting access barriers even after regulatory approval.
In the G20, among 7 commercial CAR T products with 18 FDA-approved indications, <48% (122/252) of these indications are publicly reimbursed.
This finding is one of many signals tracked across Healthcare. The live feed updates every few hours with new authority voices, debates, and emerging ideas.
← Back to Healthcare